Serum levels of CCL22 were decreased in CTCL patients who responded to bexarotene therapy, but were increased in CTCL patients who showed progressive disease 4 weeks after starting bexarotene therapy (Figure 3A). Here, CCL22 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.